Senseonics Third Quarter 2026 Earnings Call - SENSEONICS HOLDINGS INC

Financial Performance:

• Q3 2026 revenue reached $19.6 million, a 140% year-over-year increase, with U.S. revenue up 160% ($16.8M) and international revenue up 65% ($2.8M).
• Full-year 2026 revenue guidance raised to $68M–$70M (previously $62M–$66M); first nine months total revenue was $45.8M, up 118% YoY.
• Gross profit for Q3 was $12.1M with a gross margin of 62% (vs. 43% in Q3 2025), driven by a favorable mix shift toward the higher-ASP bundled pay channel (65% of volume).
• Q3 operating expenses were $44.0M ($11.7M R&D, $32.3M SG&A); Net loss was $32.7M ($0.50/share), compared to $19.5M ($0.43/share) in the prior year.
• Cash position remains strong at $126.6 million (cash, equivalents, and short-term investments) with $56.2M debt outstanding; full-year operating expenses expected slightly above the prior $160M high end due to transition service agreements.
• Full-year gross margin guidance updated to north of 60%, with a projected 60/40 split between bundled pay and DME channels.

Guidance and Future Outlook:

• Management projects Senseonics will be a $100 million revenue company in 2027.
• Q4 2026 gross margins expected to remain consistent with Q3 levels (~62%), supported by the full quarter presence of Eversense 365 in Europe despite a shift back to a 60/40 reimbursement mix.
• Freedom system gross margins targeted to be north of 70% upon launch, anticipated to drive significant operating leverage.
• Cash flow break-even is targeted for shortly after the launch of the Freedom system, leveraging its high-margin profile.
• Full 2027 guidance will be provided at the beginning of the next year.

Business Segments and Product Lines:

• Eversense 365: Driving growth with record new patient starts; 9 out of 10 new insertions are switching from competitor sensors. Retention is strong, with 94% completing the full year and significant multi-year usage rates (75%+ for second sensor, 85%+ for third).
• Commercial Expansion: Direct-to-consumer (DTC) remains the primary driver of new starts; active prescribers grew over 90% YoY.
• EonCare Insertion Network: Surpassed year-end goal of 100 inserters, now exceeding 120, with EonCare performing over 40% of all insertions to facilitate DTC conversion and geographic expansion.
• Pump Integrations: Successfully launched integration with Tandem Diabetes Care's "Twist" pump; new partnership with Beta Bionics for the "islet" bionic pancreas expected to launch immediately, with patients potentially treated by year-end.
• Pipeline Innovation: Human testing began October 26 for "Freedom," a year-long, invisible CGM with no on-body component; pivotal studies targeted for 2027 with a potential launch in 2028.

Market and Competitive Landscape:

• Market momentum driven by the unique value proposition of a full-year, removable transmitter sensor with high accuracy.
• Competitive advantage highlighted by the ability to convert patients from short-term CGM sensors and those seeking pump compatibility for Automated Insulin Delivery (AID).
• International expansion in Europe (Germany, Italy, Spain, Sweden) is accelerating with dedicated teams fully integrated post-transition from Essentia; Europe expected to represent ~15% of full-year revenue.
• Management anticipates continued conversations with additional major pump manufacturers to expand patient choice, though no specific new partners are ready for immediate announcement.

Risks and Challenges:

• Reimbursement mix volatility: While the bundled pay channel offers higher ASPs, management notes that the 60/40 split with DME remains the long-term norm, though Q4 mix is expected to be stable due to European expansion.
• Transition service agreement (TSA) costs: Significant costs related to the Essentia transition occurred in Q1–Q3, though these are winding down.
• Development timelines: The Freedom system faces a multi-year development cycle with pivotal studies in 2027 and launch in 2028.
• International adoption pace: While U.S. growth outstripped expectations, the rollout of 365-day sensors in Europe took longer than anticipated, though momentum is building.

Management Commentary and Tone:

• Tone is highly confident and optimistic, describing Q3 as a "breakout quarter" and highlighting "remarkable pace" of growth.
• Management emphasizes product differentiation as the primary growth engine, noting that "growth follows" when patients experience the superior convenience and accuracy of Eversense 365.
• Confidence in the capital allocation strategy is evident, citing strong gross profit generation funding both commercial expansion and R&D (Gemini/Freedom).
• Focus remains on expanding patient "choice" through pump partnerships and future innovations like Freedom.

Analyst Questions and Answers:

• Q4 Momentum: Management expects Q4 to follow 3Q trends with seasonal strength from deductible resets, supporting the raised full-year guidance.
• Gross Margins: Q4 margins expected to hold steady near Q3 levels despite a slight return to the 60/40 DME/bundled pay mix, due to the inclusion of a full quarter of European revenue (60/40 mix) and reduced patient assistance usage.
• Pump Partnerships: Confirmed that two pump partners (Tandem and Beta Bionics) are active; no specific numbers disclosed for Tandem, but integration is benefiting retention. Plans exist to discuss with other major pump companies.
• Retention Metrics: ~94% of patients reach the full 12-month term; retention rates for subsequent implants (2nd and 3rd sensors) remain high (75-90%).
• 2027 Revenue: Confirmed expectation to exceed $100M in revenue for 2027.
• European Expansion: EonCare model is being evaluated for potential replication in European markets, though economics differ from the U.S.
• Reorder vs. New Patients: No specific breakdown provided, but management expects reorders to remain a meaningful portion of business as the installed base doubles.

Other Key Points:

• The integration with Beta Bionics' "islet" system is a key growth catalyst for 2027, expanding the AID ecosystem for Eversense users.
• The "Freedom" project represents a strategic shift toward eliminating the on-body transmitter, aiming to redefine CGM standards.
• The company is well-positioned to achieve cash flow break-even sooner than previously anticipated, contingent on the successful launch and margin profile of Freedom.
• The Essentia commercial team transition is complete, with all global operations now managed in-house.